510 related articles for article (PubMed ID: 11502801)
1. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
Toft-Nielsen MB; Damholt MB; Madsbad S; Hilsted LM; Hughes TE; Michelsen BK; Holst JJ
J Clin Endocrinol Metab; 2001 Aug; 86(8):3717-23. PubMed ID: 11502801
[TBL] [Abstract][Full Text] [Related]
2. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
[TBL] [Abstract][Full Text] [Related]
3. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.
Toft-Nielsen MB; Madsbad S; Holst JJ
J Clin Endocrinol Metab; 2001 Aug; 86(8):3853-60. PubMed ID: 11502823
[TBL] [Abstract][Full Text] [Related]
4. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
5. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
[TBL] [Abstract][Full Text] [Related]
6. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
7. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.
Vilsbøll T; Krarup T; Deacon CF; Madsbad S; Holst JJ
Diabetes; 2001 Mar; 50(3):609-13. PubMed ID: 11246881
[TBL] [Abstract][Full Text] [Related]
8. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
[TBL] [Abstract][Full Text] [Related]
9. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.
Vaag AA; Holst JJ; Vølund A; Beck-Nielsen HB
Eur J Endocrinol; 1996 Oct; 135(4):425-32. PubMed ID: 8921824
[TBL] [Abstract][Full Text] [Related]
10. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA
J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957
[TBL] [Abstract][Full Text] [Related]
11. Hormonal Responses to Cholinergic Input Are Different in Humans with and without Type 2 Diabetes Mellitus.
Chowdhury S; Wang S; Dunai J; Kilpatrick R; Oestricker LZ; Wallendorf MJ; Patterson BW; Reeds DN; Wice BM
PLoS One; 2016; 11(6):e0156852. PubMed ID: 27304975
[TBL] [Abstract][Full Text] [Related]
12. Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations.
Nyholm B; Walker M; Gravholt CH; Shearing PA; Sturis J; Alberti KG; Holst JJ; Schmitz O
Diabetologia; 1999 Nov; 42(11):1314-23. PubMed ID: 10550415
[TBL] [Abstract][Full Text] [Related]
13. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance.
Rask E; Olsson T; Söderberg S; Holst Jj Jj; Tura A; Pacini G; Ahrén B
Metabolism; 2004 May; 53(5):624-31. PubMed ID: 15131768
[TBL] [Abstract][Full Text] [Related]
14. The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test Heralds Biomarkers of Type 2 Diabetes Risk in Obese Youth.
Kim JY; Michaliszyn SF; Nasr A; Lee S; Tfayli H; Hannon T; Hughan KS; Bacha F; Arslanian S
Diabetes Care; 2016 Aug; 39(8):1431-9. PubMed ID: 27293201
[TBL] [Abstract][Full Text] [Related]
15. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
[TBL] [Abstract][Full Text] [Related]
17. Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests.
Mari A; Gastaldelli A; Natali A; Ostergard T; Schmitz O; Ferrannini E
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E541-6. PubMed ID: 15522997
[TBL] [Abstract][Full Text] [Related]
18. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance.
Lanng S; Thorsteinsson B; Røder ME; Orskov C; Holst JJ; Nerup J; Koch C
Acta Endocrinol (Copenh); 1993 Mar; 128(3):207-14. PubMed ID: 8480468
[TBL] [Abstract][Full Text] [Related]
19. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus.
Jones IR; Owens DR; Luzio S; Williams S; Hayes TM
Diabetologia; 1989 Sep; 32(9):668-77. PubMed ID: 2676668
[TBL] [Abstract][Full Text] [Related]
20. Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy.
Andersen O; Haugaard SB; Holst JJ; Deacon CF; Iversen J; Andersen UB; Nielsen JO; Madsbad S
HIV Med; 2005 Mar; 6(2):91-8. PubMed ID: 15807714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]